Glucocorticoids and selumetinib are highly synergistic in RAS
Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM by Elizabeth C. Matheson, Huw Thomas, Marian Case, Helen Blair, Rosanna K. Jackson, Dino Masic, Gareth Veal, Chris Halsey, David R. Newell, Josef Vormoor, and Julie A. E. Irving haematol Volume 104(9): 1804 -1811 August 31, 2019 © 2019 by Ferrata Storti Foundation
Clinical features of patients and characterization of patient-derived xenografts. Elizabeth C. Matheson et al. Haematologica 2019; 104: 18041811 © 2019 by Ferrata Storti Foundation
The combination of selumetinib and dexamethasone shows synergy in vitro in RAS pathwaymutated acute lymphoblastic leukemia and is associated with enhanced levels of BIM. (A) Viability curves of Ras pathway-mutant acute lymphoblastic leukemia (ALL) cells (L. . . Elizabeth C. Matheson et al. Haematologica 2019; 104: 18041811 © 2019 by Ferrata Storti Foundation
Selumetinib and dexamethasone show synergy in vivo in RAS pathway-mutated acute lymphoblastic leukemia. Elizabeth C. Matheson et al. Haematologica 2019; 104: 18041811 © 2019 by Ferrata Storti Foundation
Pharmacodynamic analyses in acute lymphoblastic leukemia cells after drug dosing in vivo support in vitro data. Elizabeth C. Matheson et al. Haematologica 2019; 104: 18041811 © 2019 by Ferrata Storti Foundation
- Slides: 5